<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100996">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133859</url>
  </required_header>
  <id_info>
    <org_study_id>MA220414</org_study_id>
    <nct_id>NCT02133859</nct_id>
  </id_info>
  <brief_title>Adaptive Servo-ventilation Monitoring Study</brief_title>
  <official_title>Feasibilty of Respiratory Monitoring With Adaptive Servoventilation (PaceWave™) to Predict Worsening of Heart Failure in Patients With Severe Heart Failure and Sleep-disordered Breathing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep disordered breathing is very common in patients with chronic heart failure with
      reported prevalence rates of 50-75%. Adaptive Servo-Ventilation (ASV)  can be used to treat
      sleep apnea in these patients. This is an observational study to document changes in
      respiratory parameters in HF patients using ASV for a period of 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Correlation of hypoxemia, as measured by overnight pulse oximetery, with worsening heart failure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hypoxemia, as measured by pulse oximetery will be compared with heart failure status to measure if a correlation exists between hypoxemia and deterioration of heart failure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Chronic Heart Failure patients using ASV</arm_group_label>
    <description>Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Heart Failure patients using adaptive servo ventilation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        More than 18 years old Chronic heart failure (at least 12 weeks since diagnosis) according
        to the currently applicable guidelines NYHA Class III or IV at the time of inclusion with
        at least one hospitalization for heart failure in the last 12 months Moderate to severe
        sleep apnea (AHI ≥ 15/hour). Already using or willing to use ASV-therapy and able to
        tolerate the mask treatment

        Exclusion Criteria:

        Planned or scheduled heart valve interventions and/or CABG Untreated or therapy refractory
        Restless Leg Syndrome Patients for whom the use of positive airway pressure therapy may be
        contra-indicated because of symptomatic hypotension or significant intravascular volume
        depletion or pneumothorax or pneumomediastinum Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Oldenburg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruhr University of Bochum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olaf Oldenburg, MD</last_name>
    <phone>05731 / 97-1901</phone>
    <email>ooldenburg@hdz-nrw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sleep Laboratory, Ruhr University of Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>North Rhine-Westphalia</state>
        <zip>D-32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Oldenburg, MD</last_name>
      <phone>05731 / 97-1901</phone>
      <email>ooldenburg@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Olaf Oldenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
